Vertex Pharmaceuticals Inc (VRTX)
495.20
+2.94
(+0.60%)
USD |
NASDAQ |
Jul 26, 16:00
495.00
-0.20
(-0.04%)
After-Hours: 20:00
Vertex Pharmaceuticals Revenue (Quarterly): 2.691B for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 2.691B |
| December 31, 2023 | 2.518B |
| September 30, 2023 | 2.484B |
| June 30, 2023 | 2.493B |
| March 31, 2023 | 2.375B |
| December 31, 2022 | 2.303B |
| September 30, 2022 | 2.334B |
| June 30, 2022 | 2.196B |
| March 31, 2022 | 2.098B |
| December 31, 2021 | 2.073B |
| September 30, 2021 | 1.984B |
| June 30, 2021 | 1.793B |
| March 31, 2021 | 1.724B |
| December 31, 2020 | 1.628B |
| September 30, 2020 | 1.538B |
| June 30, 2020 | 1.524B |
| March 31, 2020 | 1.515B |
| December 31, 2019 | 1.413B |
| September 30, 2019 | 949.83M |
| June 30, 2019 | 941.29M |
| March 31, 2019 | 858.44M |
| December 31, 2018 | 870.11M |
| September 30, 2018 | 784.54M |
| June 30, 2018 | 752.16M |
| March 31, 2018 | 640.80M |
| Date | Value |
|---|---|
| December 31, 2017 | 651.63M |
| September 30, 2017 | 578.16M |
| June 30, 2017 | 544.14M |
| March 31, 2017 | 714.72M |
| December 31, 2016 | 458.71M |
| September 30, 2016 | 413.78M |
| June 30, 2016 | 431.61M |
| March 31, 2016 | 398.08M |
| December 31, 2015 | 417.94M |
| September 30, 2015 | 309.82M |
| June 30, 2015 | 166.08M |
| March 31, 2015 | 138.51M |
| December 31, 2014 | 144.56M |
| September 30, 2014 | 178.99M |
| June 30, 2014 | 138.42M |
| March 31, 2014 | 118.45M |
| December 31, 2013 | 351.16M |
| September 30, 2013 | 221.70M |
| June 30, 2013 | 310.75M |
| March 31, 2013 | 328.37M |
| December 31, 2012 | 333.99M |
| September 30, 2012 | 336.01M |
| June 30, 2012 | 418.30M |
| March 31, 2012 | 438.74M |
| December 31, 2011 | 563.34M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
949.83M
Minimum
Sep 2019
2.691B
Maximum
Mar 2024
1.981B
Average
2.073B
Median
Dec 2021
Revenue (Quarterly) Benchmarks
| Eli Lilly and Co | 8.768B |
| Regeneron Pharmaceuticals Inc | 3.145B |
| Pfizer Inc | 14.88B |
| Amgen Inc | 7.447B |
| Johnson & Johnson | 22.45B |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 1.100B |
| Total Expenses (Quarterly) | 1.474B |
| EPS Diluted (Quarterly) | 4.21 |
| Enterprise Value | 116.86B |
| Gross Profit Margin (Quarterly) | 87.27% |
| Profit Margin (Quarterly) | 40.87% |
| Earnings Yield | 3.11% |
| Operating Earnings Yield | 3.41% |
| Normalized Earnings Yield | 3.245 |